The serotonin hypothesis of pulmonary hypertension revisited

Advances in Experimental Medicine and Biology

Volumn 661, Issue , 2010, Pages 309-322

  MacLean, Margaret R ^a   Dempsie, Yvonne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Bone morphogenetic protein; Dexfenfluramine; Pulmonary arterial hypertension; Serotonin; Serotonin receptors; Serotonin transporter; Tryptophan hydroxylase

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 4 AMINOBUTYRIC ACID; AMINOREX; ANOREXIGENIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHLORPHENTERMINE; CITALOPRAM; DEXFENFLURAMINE; DOPAMINE; FENFLURAMINE; FLUOXETINE; GLYCINE TRANSPORTER; KETANSERIN; LY 393558; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; PHENTERMINE; REACTIVE OXYGEN METABOLITE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SUMATRIPTAN; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG; SEROTONIN AGONIST;

CELL PROLIFERATION; CONFERENCE PAPER; DRUG INHIBITION; DRUG MEGADOSE; ENZYME ACTIVATION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RISK FACTOR; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; CHEMICALLY INDUCED DISORDER; CYTOLOGY; ENDOTHELIUM CELL; GENETICS; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; VASCULARIZATION; VASOCONSTRICTION;

ANIMALS; APPETITE DEPRESSANTS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DEXFENFLURAMINE; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; LUNG; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 77951227152     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-500-2_20     Document Type: Conference Paper

References (68)

1. Simonneau G, Galiè N, Rubin LJ et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S-12S (Pubitemid 38759712)
2. Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates - implications for primary pulmonary hypertension. Circulation 100:869-875 (Pubitemid 29398887)
3. Ulus IH, Maher TJ, Wurtman RJ (2000) Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 59:1611-1621 (Pubitemid 30229896)
4. Hervé P, Launay JM, Scrobohaci ML et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249-254
5. Herve P, Drouet L, Dosquet C et al (1990) Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 89:117-120 (Pubitemid 20196727)
6. Martin F, Artigas F (1992) Simultaneous effects of para- chloroamphetamine, D-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 59:1138-1144
7. Zolkowska D, Baumann MH, Rothman RB (2008) Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 324:791-797 (Pubitemid 351185838)
8. Lee SL, Wang WW, Fanburg BL (2001) Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 15:1324-1325
9. Patnaude LA, Undem BJ, O'Rourke ST (2000) Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries. Eur J Pharmacol 401:229-234 (Pubitemid 30488201)
10. Reeve HL, Archer SL, Soper M, Weir EK (1999) Dexfenfluramine increases pulmonary smooth muscle intracellular Ca2+ independent of membrane potential. Am J Physiol Lung Cell Mol Physiol 277:L662-L666 (Pubitemid 29459687)
11. Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V et al (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-2220 (Pubitemid 26360516)
12. Rothman RB, Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88
13. Alexander SPH, Mathie A, Peters JA (2005) Guide to receptors and channels, 1st edition (2005 revision). Br J Pharmacol 144:S1-S128
14. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B (1995) Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35:541-572
15. McGoon MD, Vlietstra RE (1987) Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol 14:303-309 (Pubitemid 17024620)
16. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5Ht1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87:401-405 (Pubitemid 23040908)
17. MacLean MR, Clayton RA, Templeton AGB, Morecroft I (1996) Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 119:277-282 (Pubitemid 26326459)
18. Morecroft I, Heeley RP, Prentice HM, Kirk A (1999) MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 128:730-734 (Pubitemid 29504766)
19. Launay JM, Herve P, Peoc'h K et al (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135 (Pubitemid 35175968)
20. MacLean MR (1999) Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 20:490-495 (Pubitemid 30004021)
21. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR (2001) Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension - converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res 89:1231-1239 (Pubitemid 34627883)
22. Rondelet B, Van Beneden R, Kerbaul F et al (2003) Expression of the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 22:408-412 (Pubitemid 37098919)
23. Lawrie A, Spiekerkoetter E, Martinez EC et al (2005) Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97:227-235 (Pubitemid 41105448)
24. Kasparian A, Floros A, Gialafos E et al (2007) Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16:505-508 (Pubitemid 47242524)
25. Bailey SR, Elliott J (1998) Evidence for different 5-HT1B/1D receptors mediating vasoconstriction of equine digital arteries and veins. Eur J Pharmacol 355:175-187 (Pubitemid 28404700)
26. Susol E, MacGregor AJ, Barrett JH et al (2000) A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 43:1641-1646 (Pubitemid 30452486)
27. Bernatsky S, Pineau CA, Lee JL, Clarke AE (2006) Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus. Lupus 15:671-674 (Pubitemid 44682829)
28. Cogolludo A, Moreno L, Lodi F et al (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells - role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98:931-938
29. Welsh DJ, Harnett M, Maclean M, Peacock AJ (2004) Proliferation and signaling in fibroblasts - role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med 170:252-259 (Pubitemid 38971409)
30. Callebert J, Esteve JM, Hervé P et al (2006) Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine2B receptors in mice. J Pharmacol Exp Ther 317:724-731
31. Blanpain C, Le Poul E, Parma J, Knoop C, Detheux M, Parmentier M et al (2003) Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60:518-528 (Pubitemid 37501109)
32. Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13-25 (Pubitemid 37271085)
33. Eddahibi S, Humbert M, Fadel E et al (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108:1141-1150 (Pubitemid 32995372)
34. Eddahibi S, Chaouat A, Morrell N et al (2003) Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108:1839-1844 (Pubitemid 37296093)
35. Long L, Aldashev AA, Hensiek A et al (2002) Preliminary identification of genetic loci associated with high altitude pulmonary hypertension by association mapping. Thorax 57:S110
36. Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD (2007) Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. Am Heart J 153:426-432 (Pubitemid 46328768)
37. Machado RD, Koehler R, Glissmeyer E et al (2006) Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 173:793-797
38. Willers ED, Newman JH, Loyd JE et al (2006) Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173:798-802
39. Eddahibi S, Hanoun N, Lanfumey L et al (2000) Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105:1555-1562 (Pubitemid 30390306)
40. MacLean MR, Deuchar GA, Hicks MN et al (2004) Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109:2150-2155 (Pubitemid 38620226)
41. Guignabert C, Izikki M, Tu LI et al (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330 (Pubitemid 43948088)
42. Morecroft I, Loughlin L, Nilsen M et al (2005) Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313:539-548 (Pubitemid 40604152)
43. Sato K, Webb S, Tucker A et al (1992) Factors influencing the idiopathic development of pulmonary hHypertension in the fawn hooded rat. Am Rev Respir Dis 145:793-797
44. Marcos E, Adnot S, Pham MH et al (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:487-493 (Pubitemid 37046880)
45. Guignabert C, Raffestin B, Benferhat R et al (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111:2812-2819 (Pubitemid 40791554)
46. Laudi S, Trump S, Schmitz V et al (2007) Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:L630-L6L8
47. Marcos E, Fadel E, Sanchez O et al (2004) Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94:1263-1270 (Pubitemid 38656414)
48. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL (1994) Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 266:L46-L52
49. Liu YL, Suzuki YJ, Day RM, Fanburg BL (2004) Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95:579-586 (Pubitemid 39274372)
50. Dempsie Y, Morecroft I, Welsh DJ et al (2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117:2928-2937 (Pubitemid 351787078)
51. Walther DJ, Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673-1680 (Pubitemid 37249312)
52. Eddahibi S, Guignabert C, Barlier-Mur AM et al (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857-1864 (Pubitemid 43739397)
53. Morecroft I, Dempsie Y, Bader M et al (2007) Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:232-236 (Pubitemid 46360365)
54. Lee SL, Wang WW, Finlay GA, Fanburg BL (1999) Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277:L282-L291 (Pubitemid 29415085)
55. Suzuki YJ, Day RM, Tan CC et al (2003) Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem 278:17525-17531 (Pubitemid 36799640)
56. Lee SL, Wang WW, Fanburg BL (1998) Superoxide as an intermediate signal for serotonininduced mitogenesis. Free Radic Biol Med 24:855-858 (Pubitemid 28169573)
57. Liu JQ, Folz RJ (2004) Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol 287:L111-L118 (Pubitemid 38787657)
58. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM (2008) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155:606-616
59. Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G (2007) Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282:2918-2928 (Pubitemid 47084345)
60. Walther DJ, Peter JU, Winter S et al (2003) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115:851-862 (Pubitemid 38058497)
61. Das M, Bouchey DM, Moore MJ, Hopkins DC, Nemenoff RA, Stenmark KR (2001) Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on G protein-mediated activation of mitogen-activated protein kinases. J Biol Chem 276: 15631-15640
62. Mortimer HJ, Peacock AJ, Kirk A, Welsh DJ P38 MAP (2007) kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. Pulm Pharmacol Ther 20:718-725 (Pubitemid 47446348)
63. Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M (2002) Dexfenfluramine protects against pulmonary hypertension in rats. J Appl Physiol 93:1770-1778 (Pubitemid 36082991)
64. Rochefort GY, Lemaire MC, Eder V et al (2006) Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension. Eur J Pharmacol 550:149-154 (Pubitemid 44572268)
65. Massagué J (2003) Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev 17:2993-2997 (Pubitemid 38040762)
66. Yang XD, Long L, Southwood M et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053-1063 (Pubitemid 40791377)
67. Long L, MacLean MR, Jeffery TK et al (2006) Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98:818-827
68. Morecroft I, Pang L, Baranowska M et al (2009) In vivo effects of a combined 5-HT1B receptor/ SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res In press.